Phaseline

Targets › ROS1

ROS1 (Proto-oncogene tyrosine-protein kinase ROS): drug programs, companies and trials

12 programs from 12 companies in 41 trials: 20 Phase 2, 12 Phase 1, 7 Phase 3, 2 Phase 4; Oncology; next expected readout Jan 2027.

Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1. (UniProt, P08922)

Open in Phaseline: the race on ROS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pfizercrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
IDEAYA BiosciencesCrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
RocheEntrectinib (RXDX-101)
Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3, ROS1, ALKPhase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors …Jan 2027
Bristol-Myers SquibbRepotrectinib
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 3Carcinoma, Non-Small-Cell LungFeb 2027
Nuvation BioTaletrectinib
Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor
ROS1, NTRK1, NTRK2, NTRK3Phase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC)Jun 2027
Pingping SongWX-0593
ALK and ROS1 tyrosine kinase inhibitor
ALK, ROS1Phase 2Non-Small Cell Lung Cancer(NSCLC)Mar 2027
Ascentage Pharma GroupAPG-2449
Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor
FAK, ALK, ROS1Phase 1Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid CancerMay 2027
Xuanzhu BiopharmaceuticalXZP-5955 tablets
NTRK and ROS1 fusion inhibitor
NTRK1, NTRK2, NTRK3, ROS1Phase 1Locally Advanced or Metastatic Solid TumorsJun 2027
Turning Point TherapeuticsRepotrectinib (TPX-0005)
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 1Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced CancerSep 2027
Avistone BiotechnologyANS03
ROS1 and NTRK tyrosine kinase inhibitor
ROS1, NTRKPhase 1Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationDec 2027
Guangzhou JOYO PharmaJYP0322
ROS1 tyrosine kinase inhibitor
ROS1Phase 1Protein Kinase InhibitorsDec 2027
NuvalentZidesamtinib (NVL-520)
ROS1 inhibitor
ROS1Phase 1Locally Advanced Solid TumorDec 2027

Conditions

Advanced Lymphoma (4) Non Small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (2) Carcinoma, Non-Small-Cell Lung (2) Solid Tumors (2) Haematological Malignancy (2) Locally Advanced Solid Tumors (2) NSCLC (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Non-small Cell Lung Cancer (1)

Modalities

small molecule (12)

Companies

IDEAYA Biosciences (1) Xuanzhu Biopharmaceutical (1) Pingping Song (1) Nuvation Bio (1) Roche (1) Ascentage Pharma Group (1) Turning Point Therapeutics (1) Bristol-Myers Squibb (1) Guangzhou JOYO Pharma (1) Nuvalent (1) Pfizer (1) Avistone Biotechnology (1)

Related targets

ALK (5) NTRK1 (5) NTRK2 (5) NTRK3 (5) MET (2) EML4 (2) NPM1 (2) CD74 (2) FAK (1) NTRK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.